Your browser doesn't support javascript.
Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe.
Morales, Daniel R; Ostropolets, Anna; Lai, Lana; Sena, Anthony; Duvall, Scott; Suchard, Marc; Verhamme, Katia; Rjinbeek, Peter; Posada, Joe; Ahmed, Waheed; Alshammary, Thamer; Alghoul, Heba; Alser, Osaid; Areia, Carlos; Blacketer, Clair; Burn, Edward; Casajust, Paula; You, Seng Chan; Dawoud, Dalia; Golozar, Asieh; Gong, Menchung; Jonnagaddala, Jitendra; Lynch, Kristine; Matheny, Michael; Minty, Evan; Nyberg, Fredrik; Uribe, Albert; Recalde, Martina; Reich, Christian; Scheumie, Martijn; Shah, Karishma; Shah, Nigam; Schilling, Lisa; Vizcaya, David; Zhang, Lin; Hripcsak, George; Ryan, Patrick; Prieto-Alhambra, Daniel; Durate-Salles, Talita; Kostka, Kristin.
  • Morales DR; Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom of Great Britain and Northern Ireland.
  • Ostropolets A; Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Lai L; Department of Biomedical Informatics, Columbia University, New York, NY, USA.
  • Sena A; The University of Manchester, University of Manchester, Manchester, United Kingdom of Great Britain and Northern Ireland.
  • Duvall S; Janssen Research and Development LLC, Raritan, NJ, USA.
  • Suchard M; University of Utah Health, Epidemiology, Salt Lake City, UT, USA.
  • Verhamme K; UCLA, Biomathematics, Los Angeles, CA, USA.
  • Rjinbeek P; Erasmus MC, Medical Informatics, Erasmus MC, Dr Molewaterplein, Rotterdam, CA, The Netherlands.
  • Posada J; Erasmus MC, Medical Informatics, Erasmus MC, Dr Molewaterplein, Rotterdam, CA, The Netherlands.
  • Ahmed W; Stanford University, Medicine, Stanford, CA, USA.
  • Alshammary T; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • Alghoul H; King Saud University, Medicine, Riyadh, Saudi Arabia.
  • Alser O; Islamic University of Gaza, Medicine, Gaza, State of Palestine.
  • Areia C; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • Blacketer C; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • Burn E; Erasmus MC, Medical Informatics, Erasmus MC, Dr Molewaterplein, Rotterdam, CA, The Netherlands.
  • Casajust P; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • You SC; Trial Form Support, Real World Evidence, Barcelona, Spain.
  • Dawoud D; Ajou University, Medicine, Suwon, The Republic of Korea.
  • Golozar A; Stanford University, Medicine, Stanford, CA, USA.
  • Gong M; Johns Hopkins University, Epidemiology, Baltimore, MD, USA.
  • Jonnagaddala J; DC Technologies, DC Technologies, China.
  • Lynch K; UNSW, Public Health, Sydney, Australia.
  • Matheny M; University of Utah Health, Epidemiology, Salt Lake City, UT, USA.
  • Minty E; University of Utah Health, Epidemiology, Salt Lake City, UT, USA.
  • Nyberg F; University of Calgary, Public Health, Calgary, Alberta, Canada.
  • Uribe A; University of Gothenburg, Public health, Goteborg, Sweden.
  • Recalde M; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • Reich C; IDIAP Jordi Gol, IDIAP, Barcelona, Spain.
  • Scheumie M; IQVIA, Real World Solutions, Cambridge, MA, USA.
  • Shah K; Janssen Research and Development LLC, Raritan, NJ, USA.
  • Shah N; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • Schilling L; Stanford University, Medicine, Stanford, CA, USA.
  • Vizcaya D; University of Colorado, School of Medicine, Denver, CO, USA.
  • Zhang L; Bayer Pharmaceuticals, Bayer, Spain.
  • Hripcsak G; Chinese Academy of Medical Sciences and Peking Union Medical College, Public health, Beijing, China.
  • Ryan P; Department of Biomedical Informatics, Columbia University, New York, NY, USA.
  • Prieto-Alhambra D; Janssen Research and Development LLC, Raritan, NJ, USA.
  • Durate-Salles T; Department of Orthopedics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • Kostka K; IDIAP Jordi Gol, IDIAP, Barcelona, Spain.
J Asthma ; : 1-11, 2022 Feb 11.
Article in English | MEDLINE | ID: covidwho-2272828
ABSTRACT

Objective:

Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.

Methods:

We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients ('diagnosed' and 'hospitalized') based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.

Results:

The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6-8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7-6.8) to 18.5% (95% CI 18.2-18.8) in the diagnosed cohort and 5.2% (95% CI 4.0-6.8) to 20.5% (95% CI 18.6-22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8-2.4) to 16.9% (95% CI 13.8-20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15-30% of hospitalized COVID-19 asthma patients.

Conclusion:

The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.[Box see text]Supplemental data for this article is available online at https//doi.org/10.1080/02770903.2021.2025392 .
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: J Asthma Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: J Asthma Year: 2022 Document Type: Article